Form 4: Korro Bio Director Forest Baskett Acquires Shares Via Subscription Agreement

Forest Baskett, a director at Korro Bio, acquired 17,857 shares of common stock on April 22, 2024, through a subscription agreement.

Summary

• On April 22, 2024, Forest Baskett, a director of Korro Bio, acquired 17,857 shares of common stock at a price of $56 per share.
• The acquisition was made pursuant to a subscription agreement dated April 17, 2024.
• Following the transaction, Baskett indirectly owns 1,090,793 shares through NEA 17 GP, LLC, NEA Partners 17, L.P., and New Enterprise Associates 17, L.P. ('NEA 17').
• Baskett disclaims beneficial ownership of the securities held by NEA 17, except to the extent of any pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a director, which could be interpreted as a positive sign of confidence, but it's not overwhelmingly positive or negative.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

This transaction is a routine disclosure of insider trading activity, which is common in the biopharmaceutical industry. Directors and officers often buy or sell shares of their companies, and these transactions are closely monitored by regulators and investors.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, aligning with SEC regulations and industry norms.
• The size of the transaction (17,857 shares) is relatively small compared to some insider transactions in larger pharmaceutical companies, but it is significant for a company of Korro Bio's size.

Stakeholder Impact

• The share acquisition could have a minor positive impact on shareholder sentiment.

Key Dates